In a new move for agricultural science and climate change mitigation, Lucidome Bio, a New Zealand-based biotech firm, has secured $13.5 million in funding to propel the next phase of the country’s pioneering methane vaccine research. The investment, which includes $8.5 million from AgriZeroNZ and $5 million from the New Zealand Agricultural Greenhouse Gas Research Centre (NZAGRC), underscores the critical importance of developing a sustainable solution to methane emissions from livestock—a significant contributor to global greenhouse gases.
A Transformative Vision for Global Agriculture
Wayne McNee, Chief Executive of AgriZeroNZ, emphasized the transformative potential of the methane vaccine for New Zealand’s agricultural sector and beyond. “A vaccine that reduces methane from ruminant animals would be a transformational tool for New Zealand’s agricultural sector and for farmers worldwide,” said McNee. He highlighted the vaccine as a “holy grail” solution due to its potential to provide a low-cost, high-impact method of reducing emissions across all farming systems.
The support from AgriZeroNZ follows prior investments aimed at establishing Lucidome Bio as a leader in attracting international investors and accelerating the development of this innovative technology. “We’re really pleased to be backing Lucidome Bio, alongside the NZAGRC, in a shared effort to get a vaccine to farmers sooner,” McNee added.
Innovative Science Targeting Methane Reduction
The proposed methane vaccine works by triggering an animal's immune system to produce antibodies in its saliva that suppress the growth and activity of methane-producing microbes, known as methanogens, in the rumen. This innovative approach could significantly reduce the amount of methane—a potent greenhouse gas—released into the atmosphere from livestock.
Naomi Parker, Executive Director of NZAGRC, acknowledged the challenges associated with this research, particularly due to the complex nature of the rumen and the need for effective antibody production in saliva. Despite these hurdles, she expressed confidence in the progress made to date. “We’re proud to be long-standing supporters of this work and help Lucidome Bio achieve a world-first by turning the vaccine’s research legacy into a safe and effective tool for farmers,” Parker said.
Building on a Legacy of Research and Collaboration
Lucidome Bio, an entity established by AgriZeroNZ, aims to consolidate New Zealand’s expertise in vaccine technology, intellectual property, and funding to develop a commercially viable methane vaccine. The company builds on the pioneering research led by AgResearch’s team of globally recognized immunologists and microbiologists. AgResearch, a key partner in this initiative, will continue to provide expertise and support, with scientists being seconded to Lucidome Bio and access to state-of-the-art research facilities.
David Aitken, Interim Chief Executive of Lucidome Bio, welcomed the funding as a significant step towards technological innovation in addressing one of the world’s biggest climate change challenges. “We know farmers are looking for effective and affordable ways to reduce methane. Our vision is to help farmers feed the world while protecting our planet,” said Aitken. “This funding will allow us to build the team, carry out field trials in animals, and progress development of the vaccine for farmers.”
International Collaboration and Global Implications
The investment in Lucidome Bio follows a recent announcement of additional funding from the Bezos Earth Fund, which granted USD $9.4 million to an international consortium led by researchers from the Pirbright Institute and the Royal Veterinary College. This consortium aims to build a robust scientific foundation for the methane vaccine, with AgResearch scientists contributing their expertise in rumen microbiology and immunology.
The global interest and investment in New Zealand’s methane vaccine research highlight its potential to revolutionize agricultural practices worldwide. By reducing methane emissions from ruminant livestock, the vaccine could play a crucial role in meeting international climate targets and promoting sustainable agricultural practices.
A Path Forward
As the world grapples with the urgent need to reduce greenhouse gas emissions, the work being done by Lucidome Bio and its partners represents a beacon of hope. The development of a methane vaccine is not only a scientific and technological challenge but also a critical opportunity to transform the agricultural sector and significantly impact global efforts to combat climate change.
With continued support from organizations like AgriZeroNZ and NZAGRC, and the collaboration of international partners, Lucidome Bio is well-positioned to lead the way in developing a practical solution to one of the most pressing environmental issues of our time. The journey to a methane vaccine is long and complex, but the potential rewards—for both the planet and future generations—are immeasurable.
Comments